Amivantamab is a fully humanized, bispecific immunoglobulin G1 antibody, directed against both EGFR and MET receptor, which was shown to block ligand binding, promote receptor degradation, and trigger antibody-dependent cellular cytotoxicity in models of EGFR mutation-positive NSCLC.68 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.